<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="201511">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00466609</url>
  </required_header>
  <id_info>
    <org_study_id>05/55628-8</org_study_id>
    <secondary_id>2005/55628-08</secondary_id>
    <nct_id>NCT00466609</nct_id>
  </id_info>
  <brief_title>Using Drug Augmentation to Treat Obsessive Compulsive Disorder Patients Who Did Not Respond to Previous Treatment</brief_title>
  <acronym>EPMTOC</acronym>
  <official_title>Pharmacological Augmentation Strategies for Obsessive Compulsive Disorder Patients Non-respondent to First Line Medication Treatment: a Double Blind Placebo Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sao Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fundação de Amparo à Pesquisa do Estado de São Paulo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Conselho Nacional de Desenvolvimento Científico e Tecnológico</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Sao Paulo</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This will be a controlled, randomized, double-blind and double-dummy study on the treatment
      augmentation strategy for obsessive compulsive disorder patients non-respondent to first
      line pharmacological treatment. The investigators will compare: fluoxetine maintenance at
      maximum dosage for additional 12 weeks; the association of fluoxetine with quetiapine; and
      the association of fluoxetine with clomipramine.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Arm 1: SSRI (Fluoxetine 40mg* once a day) + Clomipramine 75mg* once a day.

      Arm 2: SSRI (Fluoxetine 40mg* once a day) + Quetiapine 200mg* once a day.

      Arm 3: SSRI (Fluoxetine 80mg* once a day) + Placebo once a day.

      *or maximum tolerated dose

      We hypothesize that quetiapine and clomipramine will be effective augmentation strategies
      for resistant OCD patients in comparison to placebo.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2007</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rates of improvement after 12 weeks of treatment based on the difference of initial and final Yale Brown Obsessive Compulsive Scale (YBOCS) scores for obsessions and compulsions</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement of quality of life (QOL) will be assessed through SF-36 administered on weeks 0 and 12;</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of social adaptation using the Social Adaptation Scale (SAS) (Weissman &amp; Payket, 1974) administered on weeks 0 and 12</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability of the proposed treatments through adverse events follow-up performed each visit (emphasis in serotonergic syndrome)</measure>
    <time_frame>weeks 0,1,2,3,4,8,12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Score obtained with Beck depression inventory (BDI)</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Score obtained with Beck´s anxiety inventory (BAI)</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical global impression measure of improvement</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline EKG regarding QT interval</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fluoxetine dosage and Clomipramine dosage (when applies)</measure>
    <time_frame>weeks 2 and 12</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Obsessive Compulsive Disorder</condition>
  <arm_group>
    <arm_group_label>Quetiapine augmentation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>fluoxetine up to 40mg once a day plus Quetiapine up to 200mg once a day, during 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clomipramine augmentation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fluoxetine up to 40mg once a day plus clomipramine up to 75mg once a day, during 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Fluoxetine up to 80 mg once a day plus placebo 3 pills once a day, during 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>clomipramine and fluoxetine</intervention_name>
    <description>Clomipramine at maximum dosage of 75mg per day plus fluoxetine at maximum dosage of 40mg per day</description>
    <arm_group_label>Clomipramine augmentation</arm_group_label>
    <other_name>Anafranil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>quetiapine and fluoxetine</intervention_name>
    <description>Quetiapine at maximum tolerated dosage of 200mg per day plus fluoxetine at maximum dosage of 40mg per day</description>
    <arm_group_label>Quetiapine augmentation</arm_group_label>
    <other_name>Seroquel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo and fluoxetine</intervention_name>
    <description>Placebo plus fluoxetine at maximum dosage of 80mg per day</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Prozac</other_name>
    <other_name>Daforin (EMS pharmaceutics)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. OCD diagnosis

          2. YBOCS score ≥ 16 (for patients with both obsessions and compulsions) or ≥ 10 (for
             patients with only obsessions or compulsions)

          3. Previously signed informed consent to participate in this clinical trial

        Exclusion Criteria:

          1. Patients with clinical or neurological diseases that may be worsen by the medications
             included in treatment protocol

          2. Current substance dependence or abuse

          3. Current psychotic symptoms

          4. Current suicide risk

          5. Current pregnancy or intention to get pregnant before the end of the treatment
             protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juliana B Diniz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Sao Paulo Medical School</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institute of Psychiatry</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <zip>05403-010</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <link>
    <url>http://www.protoc.com.br</url>
    <description>Main research group involved in this study</description>
  </link>
  <verification_date>May 2010</verification_date>
  <lastchanged_date>May 12, 2010</lastchanged_date>
  <firstreceived_date>April 26, 2007</firstreceived_date>
  <responsible_party>
    <name_title>Juliana Belo Diniz</name_title>
    <organization>University of São Paulo</organization>
  </responsible_party>
  <keyword>clomipramine</keyword>
  <keyword>quetiapine</keyword>
  <keyword>fluoxetine</keyword>
  <keyword>placebo</keyword>
  <keyword>augmentation</keyword>
  <keyword>obsessive compulsive disorder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Compulsive Personality Disorder</mesh_term>
    <mesh_term>Obsessive-Compulsive Disorder</mesh_term>
    <mesh_term>Compulsive Behavior</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fluoxetine</mesh_term>
    <mesh_term>Clomipramine</mesh_term>
    <mesh_term>Quetiapine Fumarate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
